CD2314
![]() | |
| Clinical data | |
|---|---|
| Other names | CD-2314; CD 2314 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H24O2S |
| Molar mass | 364.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CD2314 is a drug which acts as a retinoic acid receptor β (RARβ) agonist. It is used for research into the function of RARβ and promotes nerve repair following injury.[1][2]
References
- ↑ Duprey-Díaz MV, Blagburn JM, Blanco RE (9 September 2016). "Exogenous Modulation of Retinoic Acid Signaling Affects Adult RGC Survival in the Frog Visual System after Optic Nerve Injury". PLOS ONE. 11 (9) e0162626. Bibcode:2016PLoSO..1162626D. doi:10.1371/journal.pone.0162626. PMC 5017682. PMID 27611191.
- ↑ Miro Estruch I, Melchers D, Houtman R, de Haan LH, Groten JP, Louisse J, et al. (September 2017). "Characterization of the differential coregulator binding signatures of the Retinoic Acid Receptor subtypes upon (ant)agonist action". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1865 (9): 1195–1206. doi:10.1016/j.bbapap.2017.06.011. PMID 28642153.
